DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT)’s share price gapped up before the market opened on Friday . The stock had previously closed at $20.06, but opened at $21.49. DBV Technologies shares last traded at $20.80, with a volume of 110,344 shares trading hands.

Analyst Ratings Changes

DBVT has been the subject of a number of research analyst reports. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. HC Wainwright set a $40.00 price target on DBV Technologies in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.25.

DBV Technologies Stock Performance

The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -3.97 and a beta of -0.97. The company has a 50 day moving average price of $21.16 and a 200 day moving average price of $16.54.

Insider Transactions at DBV Technologies

In other DBV Technologies news, major shareholder Bpifrance Epic sold 2,076,990 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total value of $10,073,401.50. Following the completion of the sale, the insider owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 3,369,627 shares of company stock valued at $15,489,908 in the last 90 days. 1.44% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DBV Technologies

A number of large investors have recently modified their holdings of the company. Vivo Capital LLC acquired a new stake in DBV Technologies in the 2nd quarter valued at $9,659,000. MPM Bioimpact LLC bought a new stake in DBV Technologies during the 2nd quarter valued at $9,649,000. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies during the second quarter worth $9,659,000. Octagon Capital Advisors LP acquired a new position in DBV Technologies during the second quarter worth $9,315,000. Finally, New York State Common Retirement Fund bought a new position in shares of DBV Technologies in the third quarter valued at $34,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.